longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

ALK

002940

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 40.70, within the reasonable range, cheaper than 42.46% of the time in the past 3 years, and the industry ranks 95/221, the industry Median 23.00.

40.7xP/E
¥23.09Stock price
¥0.57Earnings per share
40.7xP/E
Stock price¥23.09Earnings per share¥0.57

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
36.10x
Typical range
25.38x–65.17x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.00x
011223344

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.00x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
300765SZCSPC Innovation
58.23x715.52%¥59.55B
002821SZAsymchem
57.16x18.79%¥59.20B
002294SZSalubris
49.77x29.31%¥33.52B
300558SZBETTA PHARMACEUTICALS
41.25x90.41%¥19.29B
002755SZASK PHARM
52.33x--¥10.32B
300725SZPHARMABLOCK
45.63x18.18%¥9.61B
000756SZXinhua Pharm
41.46x--¥8.92B
600789SHLKPC
54.80x--¥7.87B
600195SHCAHIC
50.03x19.19%¥6.97B
688553SHHUIYU PHARMACEUTICAL
59.44x--¥6.74B
301393SZHighfine
54.28x--¥5.94B
002390SZxinbang phar.
51.07x--¥5.75B
002940SZALK
40.70x--¥4.66B
600628SHSNW
59.99x--¥4.11B
301509SZKingchem
51.26x--¥3.25B
603079SHSHENGDA BIO-PHARM
52.06x--¥2.34B
600851SHHX GROUP
50.95x--¥10.08B
900904SHShenqi
57.15x--¥233.39M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.